Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
<p>Pharmacokinetic profile for EnaV in dose-escalation phase. Plasma/serum concentrations of (A) conjugated EnaV and (B) MMAE at 3Q4W. Dots indicate observed data; lines indicate mean data. EnaV, enapotamab vedotin; LLOQ, lower limit of quantitation; MMAE, monomethyl auristatin E</p>
Furkejuvvon:
| Váldodahkki: | |
|---|---|
| Eará dahkkit: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Almmustuhtton: |
2025
|
| Fáttát: | |
| Fáddágilkorat: |
Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
Lasit vuosttaš kommeantta. Visot kommeanttat leat almmolaččat.!